Table 1. Clinical presentation and... | American Society of Hematology

Table 1.

Clinical presentation and laboratory findings in untreated patients with acute TMA

Patient ID	Diagnosis	Age	Sex	Platelets, × 10⁹/L	ADAMTS13 activity, %	Inhibitor, BU/mL	IgG titer	IgM titer
P1	Post-ticlopidine TMA	68	M	14	< 5	Neg	3200	400
P2	Cancer-associated TMA	39	M	NA	8	Neg	1600	100
P3	Idiopathic TTP	70	F	9	< 3	Neg	600	400
P4	Idiopathic TTP	35	F	9	< 6	Neg	300	Neg
P5	Idiopathic TTP	62	F	NA	< 3	Neg	400	Neg
P6	Idiopathic TTP	56	M	57	< 6	Neg	200	Neg
P7	Idiopathic TTP	58	F	92	< 6	1.5	Neg	Neg
P8	Idiopathic TTP	36	F	13	14	2	20	Neg
P9	Idiopathic TTP	32	F	10	16	ND	1600	Neg
P10	Idiopathic TTP	17	F	59	11	1.5	3200	Neg
P11	Unspecified TMA	34	M	NA	35	ND	Neg	100
P12	HUS	23	M	36	79	Neg	Neg	400
P13	HUS	0.5	M	NA	40	ND	Neg	100

Patient ID	Diagnosis	Age	Sex	Platelets, × 10⁹/L	ADAMTS13 activity, %	Inhibitor, BU/mL	IgG titer	IgM titer
P1	Post-ticlopidine TMA	68	M	14	< 5	Neg	3200	400
P2	Cancer-associated TMA	39	M	NA	8	Neg	1600	100
P3	Idiopathic TTP	70	F	9	< 3	Neg	600	400
P4	Idiopathic TTP	35	F	9	< 6	Neg	300	Neg
P5	Idiopathic TTP	62	F	NA	< 3	Neg	400	Neg
P6	Idiopathic TTP	56	M	57	< 6	Neg	200	Neg
P7	Idiopathic TTP	58	F	92	< 6	1.5	Neg	Neg
P8	Idiopathic TTP	36	F	13	14	2	20	Neg
P9	Idiopathic TTP	32	F	10	16	ND	1600	Neg
P10	Idiopathic TTP	17	F	59	11	1.5	3200	Neg
P11	Unspecified TMA	34	M	NA	35	ND	Neg	100
P12	HUS	23	M	36	79	Neg	Neg	400
P13	HUS	0.5	M	NA	40	ND	Neg	100

Patients 1 to 7 presented with severe ADAMTS13 deficiency (< 10% of normal); discrepant results between the ADAMTS13 inhibitor assay and ELISA results for anti-ADAMTS13 IgG and IgM antibodies are shown. Patients 8 to 13 presented without severe ADAMTS13 deficiency (> 10% of normal); anti-ADAMTS13 IgG or IgM antibodies detected by ELISA are shown.

M indicates male; Neg, negative; NA, not available; F, female; and ND, not determined.

View Large

This Feature Is Available To Subscribers Only